- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
High Drug Sales Drive Strong Second Quarter for Bristol-Myers
Bristol-Myers Squibb (NYSE:BMY) experienced a stronger than anticipated second quarter, with strong sales for new heart, hepatitis C, and cancer medicines increasing revenues.
Bristol-Myers Squibb (NYSE:BMY) experienced a stronger than anticipated second quarter, with strong sales for new heart, hepatitis C, and cancer medicines increasing revenues.
According to an article on Pharmaceutical Processing:
Bristol-Myers’ recent purchase of startup Flexus Biosciences Inc. resulted in an $869 million charge, plus most of the tax bill and quarterly loss. But it gives Bristol-Myers a company trying to develop immuno-oncology drugs with a different mechanism than Opdivo and Yervoy.
Excluding the acquisition charge and other one-time items, Bristol-Myers posted adjusted income of $890 million, or 53 cents per share. Analysts surveyed by FactSet were expecting 36 cents, on average.
The $130 million net loss amounted to 8 cents per share. In 2014’s second-quarter, Bristol-Myers posted net income of $333 million, or 20 cents per share.
Click here to read the full article on Pharmaceutical Processing.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.